Loading
A phase 2 trial of LN-145 in non-small-cell lung cancer, run by Iovance Biotherapeutics, Inc., now recruiting.
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer is a phase 2 interventional study registered as NCT04614103 by Iovance Biotherapeutics, Inc., with 170 participants planned, started 2021-05-07 and due to reach its primary completion in 2030-12. Interventions recorded: LN-145.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Iovance Biotherapeutics, Non-small-cell lung cancer and the tag pipeline.
Shares Iovance Biotherapeutics and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/